C121P: Guselkumab Biosimilar, Human IL-23 Monoclonal Antibody

Catalog No.: C121P | **Product Name:** Guselkumab Biosimilar, Human IL-23 Monoclonal Antibody

The research grade Guselkumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C121P
Product Name	Guselkumab Biosimilar, Human IL-23 Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Interleukin 12, IL-12, IL12, IL23, IL-23, p70, IL12B, IL-12p40, Interleukin 23
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1 lambda.
Source/Host	The anti-human IL-23 monoclonal antibody guselkumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade guselkumab biosimilar specifically binds to the IL-23 protein.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by guselkumab.
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Guselkumab Biosimilar, Human IL-23 Monoclonal Antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Guselkumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is guselkumab biosimilar research grade? Guselkumab (trade name Tremfya) is a human IgG1 lambda monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23). IL-23 is a key cytokine in the pathogenesis of plaque psoriasis and other inflammatory diseases, promoting the differentiation and maintenance of Th17 cells. By inhibiting IL-23, guselkumab reduces the production of pro-inflammatory cytokines such as IL-17A, IL-17F, and IL-22. Guselkumab is indicated for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis in adults. Guselkumab biosimilar uses the same protein sequences as the therapeutic antibody guselkumab.